Exebacase for patients with Staphylococcus aureus bloodstream infection and endocarditis

Vance G. Fowler, Anita F. Das, Joy Lipka-Diamond, Raymond Schuch, Roger Pomerantz, Luis Jáuregui-Peredo, Adam Bressler, David Evans, Gregory J. Moran, Mark E. Rupp, Robert Wise, G. Ralph Corey, Marcus Zervos, Pamela S. Douglas, Cara Cassino

Research output: Contribution to journalArticlepeer-review

71 Scopus citations


BACKGROUND. Novel therapeutic approaches are critically needed for Staphylococcus aureus bloodstream infections (BSIs), particularly for methicillin-resistant S. aureus (MRSA). Exebacase, a first-in-class antistaphylococcal lysin, is a direct lytic agent that is rapidly bacteriolytic, eradicates biofilms, and synergizes with antibiotics. METHODS. In this superiority-design study, we randomly assigned 121 patients with S. aureus BSI/endocarditis to receive a single dose of exebacase or placebo. All patients received standard-of-care antibiotics. The primary efficacy endpoint was clinical outcome (responder rate) on day 14. RESULTS. Clinical responder rates on day 14 were 70.4% and 60.0% in the exebacase + antibiotics and antibiotics-alone groups, respectively (difference = 10.4, 90% CI [-6.3, 27.2], P = 0.31), and were 42.8 percentage points higher in the prespecified exploratory MRSA subgroup (74.1% vs. 31.3%, difference = 42.8, 90% CI [14.3, 71.4], ad hoc P = 0.01). Rates of adverse events (AEs) were similar in both groups. No AEs of hypersensitivity to exebacase were reported. Thirty-day all-cause mortality rates were 9.7% and 12.8% in the exebacase + antibiotics and antibiotics-alone groups, respectively, with a notable difference in MRSA patients (3.7% vs. 25.0%, difference = -21.3, 90% CI [-45.1, 2.5], ad hoc P = 0.06). Among MRSA patients in the United States, median length of stay was 4 days shorter and 30-day hospital readmission rates were 48% lower in the exebacase-treated group compared with antibiotics alone. CONCLUSION. This study establishes proof of concept for exebacase and direct lytic agents as potential therapeutics and supports conduct of a confirmatory study focused on exebacase to treat MRSA BSIs. TRIAL REGISTRATION. Clinicaltrials.gov NCT03163446. FUNDING. ContraFect Corporation.

Original languageEnglish (US)
Pages (from-to)3750-3760
Number of pages11
JournalJournal of Clinical Investigation
Issue number7
StatePublished - Jul 1 2020

ASJC Scopus subject areas

  • General Medicine


Dive into the research topics of 'Exebacase for patients with Staphylococcus aureus bloodstream infection and endocarditis'. Together they form a unique fingerprint.

Cite this